AbbVie inks immune disorder drug licensing deal with China's FutureGen

U.S. drugmaker AbbVie (ABBV.N)] will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies said on Thursday.